Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers


Autoria(s): SILVA, Pamela S.; FONTANA, Vanessa; PALEI, Ana C. T.; SERTORIO, Jonas T. C.; BIAGI, Celso; TANUS-SANTOS, Jose Eduardo
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2011

Resumo

The antihypertensive effects of angiotensin-converting enzyme inhibitors (ACEi) are explained, at least in part, by enhanced bradykinin-dependent nitric oxide (NO) formation and decreased angiotensin II-induced oxidative stress and vasoconstriction. We examined for the first time whether treatment with enalapril increases the plasma levels of markers of NO formation and decreases oxidative stress in mild to moderate hypertensive patients. Eighteen untreated hypertensive patients were treated with enalapril 10 mg/day (n = 10) or 20 mg/day (n = 8) for 60 days. Eighteen normotensive healthy controls were followed for the same period. Venous blood samples were collected at baseline and after 30/60 days of treatment with enalapril. Plasma NOx (nitrites + nitrates) concentrations were determined by using the Griess reaction. Plasma nitrite and whole blood nitrite concentrations were determined by using an ozone-based chemiluminescence assay. Plasma thiobarbituric acid-reactive species (TBARS) and 8-isoprostane concentrations were determined by a fluorimetric method and by ELISA, respectively. Treatment with enalapril decreased blood pressure in hypertensive patients. However, we found no significant changes in plasma NOx, nitrite, whole blood nitrite, and in the levels of markers of oxidative stress in both normotensive controls and hypertensive patients treated with enalapril. Our data show that enalapril 10-20 mg/day does not affect the concentrations of relevant markers of NO formation or markers of oxidative stress in mild to moderately hypertensive subjects, despite satisfactory blood pressure control. Our findings do not rule out the possibility that ACEi may produce such effects in more severely hypertensive patients treated with higher doses of ACEi.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Identificador

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, v.67, n.4, p.365-370, 2011

0031-6970

http://producao.usp.br/handle/BDPI/24284

10.1007/s00228-011-1003-x

http://dx.doi.org/10.1007/s00228-011-1003-x

Idioma(s)

eng

Publicador

SPRINGER

Relação

European Journal of Clinical Pharmacology

Direitos

restrictedAccess

Copyright SPRINGER

Palavras-Chave #ACE inhibitors #Enalapril #Nitric oxide #Oxidative stress #Hypertension #CONVERTING-ENZYME-INHIBITOR #LONG-TERM TREATMENT #SYNTHASE GENE HAPLOTYPES #ACE-INHIBITION #ENDOTHELIAL FUNCTION #RECEPTOR BLOCKADE #ANGIOTENSIN #NO #MODULATION #BIOAVAILABILITY #Pharmacology & Pharmacy
Tipo

article

original article

publishedVersion